Cooley advised Jiangsu Hengrui Pharmaceuticals on the deal. Jiangsu Hengrui Pharmaceuticals (“Hengrui”), a global pharmaceutical company focused on scientific and technological innovation, signed a global license agreement...
Jiangsu Hengrui Pharmaceuticals’ License Agreement With Elevar Therapeutics
Jiangsu Hengrui Pharmaceuticals’ License Agreement With Merck
Cooley advised Jiangsu Hengrui Pharmaceuticals on the deal. Jiangsu Hengrui Pharmaceuticals (“Hengrui”), a global pharmaceutical company focused on scientific and technological innovation, announced its strategic collaboration...
Argenx’s $1.27 Billion Follow-On Offering
Goodwin and Freshfields advised argenx, while Cooley advised the representatives of the several underwriters on the offering. argenx SE closed its $1.27 billion follow-on offering. On July 19,...
Shoreline Biosciences’ Strategic Collaboration with BeiGene
Cooley LLP advised Shoreline Biosciences on the deal. Shoreline Biosciences, a biotechnology company developing immunotherapies for cancer and other serious diseases, announced its worldwide strategic collaboration with...